Archimed adds Barcelona PET radiopharmaceuticals maker IRAB
Based in Barcelona, the 2016-founded company produces PET radiopharmaceuticals used in clinical diagnosis, clinical trials and biomedical research.
Takeaways
- IRAB is a develops and produces PET radiopharmaceuticals for clinical diagnosis, clinical trials and biomedical research.
- Archimed is acquiring IRAB.
- The target serves clinical diagnosis, clinical trials, biomedical research across Barcelona, Spain.
PET radiopharmaceuticals developer and producer IRAB was added by Archimed, bringing a company that supplies imaging agents for clinical diagnosis, clinical trials and biomedical research.
The business was founded in 2016 and is headquartered in Barcelona, Spain.
Its products are used across care delivery and research settings where positron emission tomography agents are required.
Archimed focuses its portfolio activity on healthcare companies and supports entrepreneurs in company development.
In a separate 2026 platform transaction, Archimed agreed to acquire Esperion Therapeutics, a commercial-stage biopharmaceutical company developing non-statin LDL-lowering and rare disease therapies.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.